Emerg Infect Dis. 2018 Jul;24(7):1267-1274. doi: 10.3201/eid2407.161783.
To investigate a potential risk for multiple sclerosis (MS) after vaccination with Arepanrix, the GlaxoSmithKline AS03-adjuvanted influenza A(H1N1)pdm09 vaccine, we used the provincewide immunization registry for Manitoba, Canada, to match 341,347 persons vaccinated during the 2009 pandemic to 485,941 unvaccinated persons on age, sex, address, and a propensity score measuring the probability of vaccination. We used a previously validated algorithm to identify MS cases from provincial hospital, physician, and prescription drug claims databases. After 12 months of follow-up, the age-adjusted incidence rate of MS was 17.7 cases per 100,000 person-years in the Arepanrix cohort and 24.2 per 100,000 in the unvaccinated cohort. The corresponding adjusted hazard ratio was 0.9. We observed similar patterns when we measured incidence over the entire follow-up period. The AS03 adjuvant, a candidate for inclusion in future pandemic vaccines, does not appear to increase the short-term risk for MS when included in influenza vaccines.
为了调查接种葛兰素史克公司的 AS03 佐剂甲型 H1N1pdm09 流感疫苗（Arepanrix）后多发性硬化症（MS）的潜在风险，我们利用加拿大马尼托巴省的全省免疫登记系统，将 341347 名在 2009 年大流行期间接种疫苗的人与 485941 名未接种疫苗的人按年龄、性别、地址和衡量接种可能性的倾向评分进行匹配。我们使用了一个经过验证的算法，从省级医院、医生和处方药物索赔数据库中识别 MS 病例。在 12 个月的随访后，Arepanrix 队列的 MS 发病率校正年龄为每 100000 人年 17.7 例，未接种疫苗队列为每 100000 人年 24.2 例。相应的调整后的危险比为 0.9。当我们在整个随访期间测量发病率时，我们观察到了类似的模式。AS03 佐剂是未来大流行疫苗的候选佐剂，当包含在流感疫苗中时，似乎不会增加 MS 的短期风险。
